These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 33758332)

  • 1. An early look at selective RET inhibitor resistance: new challenges and opportunities.
    Lin JJ; Gainor JF
    Br J Cancer; 2021 May; 124(11):1757-1758. PubMed ID: 33758332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting RET alterations in non-small cell lung cancer.
    Nishikawa G; Klein MA
    Curr Probl Cancer; 2024 Apr; 49():101074. PubMed ID: 38494387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
    Lin JJ; Liu SV; McCoach CE; Zhu VW; Tan AC; Yoda S; Peterson J; Do A; Prutisto-Chang K; Dagogo-Jack I; Sequist LV; Wirth LJ; Lennerz JK; Hata AN; Mino-Kenudson M; Nardi V; Ou SI; Tan DS; Gainor JF
    Ann Oncol; 2020 Dec; 31(12):1725-1733. PubMed ID: 33007380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
    Rosen EY; Johnson ML; Clifford SE; Somwar R; Kherani JF; Son J; Bertram AA; Davare MA; Gladstone E; Ivanova EV; Henry DN; Kelley EM; Lin M; Milan MSD; Nair BC; Olek EA; Scanlon JE; Vojnic M; Ebata K; Hechtman JF; Li BT; Sholl LM; Taylor BS; Ladanyi M; Jänne PA; Rothenberg SM; Drilon A; Oxnard GR
    Clin Cancer Res; 2021 Jan; 27(1):34-42. PubMed ID: 33082208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress and challenges in RET-targeted cancer therapy.
    Hu X; Khatri U; Shen T; Wu J
    Front Med; 2023 Apr; 17(2):207-219. PubMed ID: 37131086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RET fusions in non-small-cell lung cancer: an emerging target reshaping the treatment paradigm.
    Saleh K; Khalife N; Felefly T
    Future Oncol; 2021 Apr; 17(12):1445-1448. PubMed ID: 33573417
    [No Abstract]   [Full Text] [Related]  

  • 7. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.
    Subbiah V; Shen T; Terzyan SS; Liu X; Hu X; Patel KP; Hu M; Cabanillas M; Behrang A; Meric-Bernstam F; Vo PTT; Mooers BHM; Wu J
    Ann Oncol; 2021 Feb; 32(2):261-268. PubMed ID: 33161056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.
    Sun F; McCoach CE
    Curr Treat Options Oncol; 2021 Jun; 22(8):72. PubMed ID: 34165651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Case of Resistance to Selective RET-TKI Therapy With Pleural-Genotyped MET Amplification and Response to Crizotinib.
    Chen K; Zhang F; Pan G; Sheng J; Ye J; Xu Y; Yu X; Huang Z; Fan Y
    Clin Lung Cancer; 2021 Jan; 22(1):e1-e4. PubMed ID: 32778510
    [No Abstract]   [Full Text] [Related]  

  • 10. Selpercatinib in RET-fusion positive metastatic non-small cell lung cancer: achievements and gray areas.
    Belluomini L; Avancini A; Pasqualin L; Insolda J; Sposito M; Menis J; Tregnago D; Trestini I; Ferrara MG; Bria E; Milella M; Pilotto S
    Expert Rev Anticancer Ther; 2022 Aug; 22(8):785-794. PubMed ID: 35726802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostics, therapeutics and RET inhibitor resistance for RET fusion-positive non-small cell lung cancers and future perspectives.
    Lu C; Zhou Q
    Cancer Treat Rev; 2021 May; 96():102153. PubMed ID: 33773204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The progress of KIF5B-RET fusion gene in non-small cell lung cancer].
    Jin LL; Kong H; Xie WP
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Jul; 36(7):524-6. PubMed ID: 24262090
    [No Abstract]   [Full Text] [Related]  

  • 13. RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape.
    Novello S; Califano R; Reinmuth N; Tamma A; Puri T
    Oncologist; 2023 May; 28(5):402-413. PubMed ID: 36821595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel therapeutic strategies targeting bypass pathways and mitochondrial dysfunction to combat resistance to RET inhibitors in NSCLC.
    Shiba-Ishii A; Isagawa T; Shiozawa T; Mato N; Nakagawa T; Takada Y; Hirai K; Hong J; Saitoh A; Takeda N; Niki T; Murakami Y; Matsubara D
    Biochim Biophys Acta Mol Basis Dis; 2024 Aug; 1870(6):167249. PubMed ID: 38768929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Advances in the Treatment of RET Fusion-positive Advanced Non-small Cell Lung Cancer].
    Gao Q; Su J; Xiao F; Lin X; Yang J
    Zhongguo Fei Ai Za Zhi; 2021 Dec; 24(12):853-861. PubMed ID: 34743497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
    Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
    Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment with selpercatinib after pralsetinib-related pneumonitis and intracranial failure in a patient with RET-rearranged nonsmall cell lung cancer.
    Cognigni V; Giudice GC; Bozzetti F; Milanese G; Moschini I; Casali M; Mazzaschi G; Tiseo M
    Anticancer Drugs; 2024 Jul; 35(6):559-562. PubMed ID: 38453158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How should "RET positive" NSCLC be treated?
    Smit EF
    Lung Cancer; 2017 Jun; 108():250-251. PubMed ID: 28189265
    [No Abstract]   [Full Text] [Related]  

  • 19. RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges.
    Servetto A; Esposito D; Ferrara R; Signorelli D; Belli S; Napolitano F; Santaniello A; Ciciola P; Formisano L; Bianco R
    Biochim Biophys Acta Rev Cancer; 2022 Nov; 1877(6):188810. PubMed ID: 36202311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exposure-Response Relationships for Pralsetinib in Patients with RET-Altered Thyroid Cancer or RET Fusion-Positive Nonsmall Cell Lung Cancer.
    Kassir N; McDougall D; Kuruvilla D; Kim S; Kumar S; Rahman A; Ruf T; Cheeti S; Ankrom W
    J Clin Pharmacol; 2024 Jun; 64(6):685-696. PubMed ID: 38337106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.